Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Huaier Granule for HCC after non-radical hepatectomy
NCT01760616Phase 4Terminated
- Sponsor
- Qidong Gaitianli Medicines Co., Ltd.
- Start
- Nov 2011
- Primary completion
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of huaier granule in hepatocellular carcinoma (HCC) (2 arms), sponsored by Qidong Gaitianli Medicines Co., Ltd. Primary endpoints: Time to significant progression after surgery at 3 years and Postoperative survival period at 3 years. Started Nov 2011; status: terminated.
02
Drugs
huaier granule
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01760616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01760616.